Study of D-2570 in Subjects With Non-Segmental Vitiligo (D2570-206)
A Phase 2 Multicenter, Randomized, Parallel-group, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.
연구 개요
상태
상세 설명
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety and efficacy of D-2570 in subjects with non-segmental vitiligo. The study consists of three periods: a screening period (up to 4 weeks), a 24-week double-blind treatment period, and a 24-week extension treatment period, followed by a 4-week safety follow-up period.
During the screening period, written informed consent will be obtained from each subject, and eligibility will be assessed based on predefined inclusion and exclusion criteria. Subjects who meet all eligibility criteria will be stratified according to baseline vitiligo severity (T-VASI <15 or ≥15) and disease activity (active or stable), then randomized in a 1:1:1:1 ratio to one of four treatment groups: D-2570 Group A, D-2570 Group B, D-2570 Group C, or placebo.
During the 24-week double-blind treatment period, subjects will receive once-daily oral study medication. Subjects in Groups A and B will continue the same dose in the subsequent 24-week extension period. Subjects in Group C and the placebo group will be re-randomized in a 1:1 ratio to either Group A or Group B for the extension period, maintaining the blind.
All subjects will attend study visits at protocol-specified time points, including assessments of efficacy (including T-VASI), safety (including adverse events, clinical laboratory tests, vital signs, and physical examinations), and pharmacokinetic evaluations via blood sampling. The study will conclude with an end-of-study (EOS) visit at Week 52, 4 weeks after the last dose of study medication, to collect final safety data. All subjects, investigators, and study site personnel will remain blinded to treatment assignments throughout the study.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: shilin Sha
- 전화번호: 15601826678
- 이메일: shilin.sha@inventisbio.com
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 201203
- 모병
- Huashan Hospital, Fudan University
-
연락하다:
- shilin Sha
- 전화번호: 15601826678
- 이메일: shilin.sha@inventisbio.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Voluntarily signs informed consent and complies with study procedures.
- Age 18-65 years, male or female.
- Clinical diagnosis of non-segmental vitiligo at screening.
- F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.
- Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.
Exclusion Criteria:
- - Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment.
- Over 33% facial or total vitiligo lesions with leukotrichia.
- Pregnant or breastfeeding females.
- Active, latent or inadequately treated tuberculosis infection.
- Positive HIV, active HBV/HCV infection, or untreated syphilis.
- Current or history of severe herpes infection.
- Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment.
- Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study.
- Uncontrolled thyroid disease, severe cardiovascular/cerebrovascular disease or other unstable severe systemic disorders.
- Severe psychiatric disease, suicidal ideation, or alcohol/drug abuse within 6 months.
- Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia).
- Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing.
- Clinically significant abnormal lab results: elevated liver/renal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts.
- History of severe drug hypersensitivity or drug-related toxicity.
- Any condition that may impair protocol compliance or study participation per investigator judgment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: D-2570 Dose 1 (experimental arm 1)
Subjects in this arm will receive oral D-2570 Dose 1 once daily (QD) for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose of D-2570 Dose 1 in the subsequent 24-week extension period.
|
Oral D-2570 Dose 1 administered once daily for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose in the 24-week extension period
|
|
실험적: D-2570 Dose 2 (experimental arm 2)
Subjects in this arm will receive oral D-2570 Dose 2 once daily (QD) for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose of D-2570 Dose 2 in the subsequent 24-week extension period
|
Oral D-2570 Dose 2 administered once daily for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose in the 24-week extension period.
|
|
실험적: D-2570 Dose 3 (experimental arm 3)
Subjects in this arm will receive oral D-2570 Dose 3 once daily (QD) for 24 weeks during the double-blind treatment period.
After 24 weeks, subjects will be re-randomized to either D-2570 Dose 1 or Dose 2 once daily for the extension period.
|
Oral D-2570 Dose 3 administered once daily for 24 weeks during the double-blind treatment period.
Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
|
|
위약 비교기: placebo
Subjects in this arm will receive matching placebo once daily (QD) for 24 weeks during the double-blind treatment period.
After 24 weeks, subjects will be re-randomized to either D-2570 Dose 1 or Dose 2 once daily for the extension period.
|
Oral placebo administered once daily for 24 weeks during the double-blind treatment period.
Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI)
기간: week24
|
Change rate of facial vitiligo area, measured by F-VASI score, relative to baseline
|
week24
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change and percentage change from baseline in F-VASI
기간: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Absolute change and percentage change in facial vitiligo area, measured by F-VASI score, relative to baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects achieving F-VASI50/75/90
기간: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in F-VASI score from baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Change and percentage change from baseline in T-VASI
기간: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Absolute change and percentage change in total vitiligo area, measured by T-VASI score, relative to baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects achieving T-VASI50/75/90
기간: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in T-VASI score from baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects with F-PhGVA score 0 or 1
기간: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with F-PhGVA score of 0 (clear) or 1 (almost clear).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Proportion of subjects with T-PhGVA score 0 or 1
기간: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with T-PhGVA score of 0 (clear) or 1 (almost clear).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Proportion of subjects with VNS score 4 or 5
기간: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with VNS score of 4 (hardly noticeable) or 5 (not noticeable).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Change from baseline in DLQI score
기간: Weeks 8, 16, 24, 32, 40, and 48
|
Change in Dermatology Quality of Life Index (DLQI) score relative to baseline.
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Change from baseline in VitiQoL score
기간: Weeks 8, 16, 24, 32, 40, and 48
|
Change in Vitiligo-Specific Quality of Life (VitiQoL) score relative to baseline.
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Plasma concentrations of D-2570
기간: Through study completion (approximately Week 48)
|
Through study completion (approximately Week 48)
|
|
|
Safety of D-2570（AEs）
기간: Through study completion (approximately Week 48)
|
Through study completion (approximately Week 48)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- D2570-206
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .